Antibiotic Use in the Private Sector in France, 2015–2025

Antibiotic use in the outpatient sector declined in France in 2025 compared to 2024, according to both measurement methods: in terms of defined daily doses (DDD) per 1,000 inhabitants and per day: 19.98 in 2025, representing a 9.6% decrease compared to 2024; in terms of the number of prescriptions per 1,000 inhabitants per year: 740.9 in 2025, representing a 13.9% decrease compared to 2024; consumption remains higher among women than among men, except among those aged 65 and older; in 2025, primary care physicians are the leading prescribers of antibiotics (77.5%), followed by dentists (11.9%) and then medical specialists (9.1%); The direct dispensing of antibiotics by pharmacists following a rapid diagnostic test (RDT) exceeds 1% of prescriptions for the first time in 2025. During the 2015–2025 period, consumption expressed in DDJ decreases by 16.9%, and the number of prescriptions decreases by 23.2%. There is a sharp decline in consumption of quinolones and cephalosporins between 2015 and 2025, while broad-spectrum penicillins (amoxicillin) and sulfonamides increase. The share of restricted-use antibiotics (SPILF Group 2) remains stable. In 2025, Corsica and Provence-Alpes-Côte d’Azur (PACA) stand out as having the highest levels of antibiotic consumption and prescriptions in France, while the Pays de la Loire, Brittany, and the overseas departments (including French Guiana) have the lowest volumes, illustrating marked geographic heterogeneity.

Author(s): Ben Hmidene Ghaya, Maugat Sylvie, Opatowski Marion, Lefrançois Rémi

Publishing year: 2026

Pages: 27 p.

Collection: Monitoring Data

In relation to

Our latest news

Appel à candidatures d'experts pour le remplacement d’un membre « sage-femme » du Comité national d'experts sur la mortalité maternelle (CNEMM)

news

Call for Nominations to Fill Vacancies on the National Reference Centers...

news

Public Health France Conference: November 9, 2026

news

Shamonda Virus: First Human Case Detected in France—What Do We Know?